Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Okyo Pharma Limited (OKYO.LN)

Okyo Pharma Limited (OKYO.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments FinancialNewsMedia - Tue May 2, 2023

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END

OKYO : 1.0500 (-1.87%)
OKYO.LN : 1.400 (-24.32%)
NVS : 104.28 (+0.41%)
ALDX : 4.85 (+0.83%)
OCUL : 8.83 (+3.64%)
EYPT : 8.95 (+7.19%)
Wall Street - NYSE Stock Market American Flag
Stocks Climb Before the Open as Investors Weigh Economic Outlook, U.S. JOLTs Report in Focus Barchart - Tue Apr 4, 2023

June S&P 500 futures (ESM23) are up +0.29%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.61% this morning after three major U.S. benchmark indices finished the regular session mixed as weaker-than-expected...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
TSLA : 352.56 (+3.80%)
VORB : 0.0769 (-34.83%)
OKYO.LN : 1.400 (-24.32%)
BFLY : 3.24 (-1.52%)
AMC : 4.55 (+1.34%)
ONCT : 1.1400 (-1.72%)
EVO : 4.49 (-16.07%)
HLN : 9.65 (+1.05%)
CRBG : 31.75 (+0.89%)
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm Business Wire - Tue Aug 30, 2022

OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, plans a Q4 2022...

OKYO : 1.0500 (-1.87%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing Globe Newswire - Thu Jun 9, 2022

LONDON and NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing...

OKYO : 1.0500 (-1.87%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing Globe Newswire - Fri May 20, 2022

LONDON and BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences company focused on the discovery and...

OKYO : 1.0500 (-1.87%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing Globe Newswire - Thu May 19, 2022

LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a life sciences company focused...

OKYO : 1.0500 (-1.87%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing Globe Newswire - Wed May 18, 2022

LONDON and NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and...

OKYO : 1.0500 (-1.87%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation Globe Newswire - Tue May 17, 2022

LONDON, May 17, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), a life sciences company focused on the...

OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)
OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing Globe Newswire - Mon May 16, 2022

LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused...

OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)
OKYO Pharma ("OKYO" or the "Company") - Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Globe Newswire - Wed Apr 27, 2022

OK-101 ameliorates neuropathic corneal pain in a mouse model of ciliary nerve ligation BAM8-22 peptide analog OK-201 alleviates neuropathic corneal pain...

OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)

Barchart Exclusives

3 High-Yielding Dividend Kings to Boost Your Income in 2025 and Beyond Barchart - 55 minutes ago
These three high-quality companies are currently on sale, offering elevated yields that appeal to dividend growth investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot